Introduction {#sec1-1}
============

Essential thrombocythemia (ET) is a clonal bone marrow disease, characterized by increased production of platelets. Most patients with ET will have a somatic mutation in Janus Kinase 2 (*JAK2*), Calreticulin (*CALR*), or myeloproliferative leukemia virus oncogene (*MPL*) with subsequent upregulation of the JAK-STAT pathway. *JAK2 V617F* activating mutation is present in 50-60% of ET cases, *CALR* mutation is present in 20-25% of cases, while *MPL* mutation is present in 5% of cases. Patients who lack all three mutations are usually called triple negative. The most common mutations in *MPL* are *W515L* and *W515K.*^[@ref1]^ Other mutations were also reported such as *S505N*, *W515A* and *W515R*. We hereby report 2 cases of patients with clinical and laboratory picture of ET who carried 2 mutations that are previously unreported in the adult population.

Case Report \#1 {#sec1-2}
===============

A 55-year-old female with a past medical history of hypertension, osteoarthritis, neuropathy, and hyperlipidemia presented in consultation for thrombocytosis. She has had thrombocytosis for 8 years prior to presentation. Her laboratory exam showed a platelet count of 558k, white blood cell counts of 9.2k, and hemoglobin of 12.9 gm. She reported having occasional headaches and blurry vision, but was otherwise asymptomatic. Bone marrow biopsy showed mildly hypercellular bone marrow (70%) showing trilineage hematopoiesis with mildly increased megakaryocytes. She had adequate reticuloendothelial iron, with no ringed sideroblasts. There was no fibrosis on reticulin stain. No evidence of causes of secondary thrombocytosis was found. Molecular studies showed *MPLY252H* mutation. Other variants found were *EP300, MAP3K7, NTRK1, and YY1AP1.*

Case Report \#2 {#sec1-3}
===============

A 50-year-old female with a past medical history of diabetes, rheumatoid arthritis, and COPD was referred for thrombocytosis. Further review of laboratory data revealed that her platelet count has been elevated for 4 years prior to her referral. Platelet counts had been ranging from 518-600k. Patient has been asymptomatic and denied any history of thrombotic event. Patient declined bone marrow biopsy so molecular studies were sent from peripheral blood. Results revealed multiple abnormalities. *MPL F126fs\*5* mutation was detected. Other variants detected included *CSF1R, ERBB4, GPR124, KIT, MUTYH, NFE2L2, PIM1, PTPN6, and RNF43.* Patient was prescribed Aspirin 81 mg and has been asymptomatic with stable counts after 1 year of follow up.

Discussion and Conclusions {#sec1-4}
==========================

ET is a clonal disease characterized by marked thrombocytosis, prominent large to giant megakaryocytes in bone marrow, and absence of other identifiable causes of thrombocytosis. World Health Organization (WHO) diagnostic criteria includes absence of other clonal bone marrow disorders such as chronic myeloid leukemia and other myeloproliferative neoplasms. The demonstration of clonal markers favors the diagnosis. *JAK2*, *CALR* and *MPL* mutations are the most common. Subsequently the JAK-STAT pathway gets upregulated with further stimulation to cell growth and hematopoiesis. Some of the triple negative cases will have an unusual mutation in *JAK2*, *CALR* or *MPL* on whole gene sequencing.^[@ref2]^ Other mutations in different genes such as *ASXL1*, *TET2*, and *CBL* have been reported in patients with MPN. These can exist with other more common gene mutations and are helpful to establish clonality.

The *MPL* gene encodes for a transmembrane receptor that is highly expressed in CD34+ hematopoietic cells and in the megakaryocytic lineage. The murine *v-MPL* gene was discovered in 1990. Shortly afterwards its human homolog *c-MPL* was cloned.^[@ref3]^ The human c-*MPL* gene contains 12 exons. The two cytokine receptor domains are encoded for by eight exons (2-9), the cytoplasmic domain is encoded for by two exons (11-12), and the trans-membrane domain is encoded for by exon 10. Exon 1 encodes for signal peptide.^[@ref3]^ The gene encodes for a 635 amino acid transmembrane domain (CD 110). Binding of thrombopoietin to the extracellular domain for MPL leads to dimerization of the receptor and activation of the JAK-STAT pathway. [Figure 1](#fig001){ref-type="fig"} illustrates the structure of human MPL receptor.

Disruption of the juxtamembrane region of the thrombopoietin receptor MPL leads to receptor activation in the absence of receptor binding by thrombopoietin.^[@ref4]^ Mutations have been reported in the *MPL* gene. The *MPL W515L* mutation has been linked to ET. Transplanting bone marrow cells that express this mutation into mice leads to marked thrombocytosis and splenomegaly, as well as other features associated with MPN.^[@ref5]^ The *MPL W515K* mutation was discovered several months after *MPL W515L*, and was shown to be linked to the clinical picture of myeloproliferative neoplasms.^[@ref1]^

Beer *et al*. performed an analysis of molecular data from a large retrospective cohort of unselected patients with ET and Primary myelofibrosis (PMF). The entire *MPL* coding region in 18 patients with ET and 2 patients with PMF was sequenced. No mutations were found outside exon 10 in this study. Subsequently, *MPL* exon 10 in granulocyte DNA from 200 patients was sequenced. Of these, 88 had ET and 112 had PMF. Three patients with ET were found to have mutations. One had the *MPL S505N* mutation and two carried *MPL W515L* mutations. Eight out of 112 PMF patients were found to have mutations. One carried the *MPL S505N* mutation, five carried *MPL W515L* mutations, and two carried *MPL W515K* mutations.^[@ref6]^

*MPL W515A* and *MPL W515R* mutations are rare, but they are thought to function like *MPL W515K* and *L*. Given the extremely low mutation rate, the clinical significance is not confirmed.^[@ref7]^ Other mutations described are *A506T*, *L510P*, and *A519T*. The clinical significance of these mutations is still unclear.^[@ref8]^

*MPL S505N* can occur of somatic origin in sporadic cases of ET, but has also been reported along with other MPL mutations in cases with hereditary thrombocythemia (HT). In such cases it is a germline mutation that is inherited in an autosomal dominant pattern.^[@ref9]^ *MPL* S505N was found to be associated with an increased risk of thrombosis and subsequently splenomegaly and bone marrow fibrosis.^[@ref10]^

Further mutations associated with HT include *MPL K39N* and *MPL P106L*. *MPL K39N* is a polymorphism reported in African Americans. Screening of more than 400 patients and controls revealed that approximately 7% of African Americans are heterozygous for this polymorphism and that patients affected had a significantly higher platelets count than controls without the polymorphism.^[@ref11]^ *MPL P106L* is another mutation that was associated with familial thrombocytosis. It was discovered in an Arab family when two siblings presented with thrombocytosis. Molecular studies in a sample of 213 people revealed that the prevalence of this mutation is 3.3% in this cohort of unrelated individuals of Arabic descent. The control group of 193 healthy German individuals had no mutation detected.^[@ref12]^ The clinical outcome of individuals with these 2 mutations (*MPL K39N* and *MPL P106L*) is still unknown. Other germline mutations that are felt to be associated with HT are *MPL V285E* and *MPL R321W*. These are 2 activating germline mutations in exon 6 of *MPL* identified in 2016 in cases initially diagnosed as ET (*R321W*) and PMF (*V285E*).^[@ref13]^

*MPL T119I*, *MPL S204F*, *MPL S204P*, and *MPL E230G* were reported in 2016. All of these mutations lead to constitutive activation of JAK-STAT signaling indicating that they are gain of function mutations^.13^ Interestingly, all these mutations are outside of exon 10. The same report identified a new somatic mutation *MPL Y591D* in exon 12 in a patient who was initially diagnosed with triple negative ET. This patient, however, developed *JAK2 V617F* mutation at 5.5 years follow-up. *MPLS204P and MPLY591N* were reported in 2016 in patients with triple negative ET. Both mutations appeared to be gain of function mutations via in vitro studies^.14^ [Table 1](#table001){ref-type="table"} summarizes the mutations reported in *MPL* gene.^[@ref13]^ The *MPL Y252H* mutation was first described in 2011 in a three-year-old African American female with a JAK2 mutation-negative ET. Exposing bone marrow cells from this patient to thrombopoietin lead to generation of megakaryocyte colonies *in vitro*. BaF3 cells with the mutation were found to have increased thrombopoietin mediated cell growth and increased cell survival upon cytokine withdrawal.^[@ref15]^

The *MPL Y252H* mutation in our case has not been reported in adults before. Based on the work of Lambert et al, this mutation was shown to be a gain of function mutation in the extracellular domain of MPL.^[@ref15]^ Our case supports this finding and documents the first reported adult case with clinical picture of ET.

Our second case documents the first clinical case report of a patient with *MPL F126fs*. This is a frame shift mutation that results in a change in the amino acid sequence of the MPL protein beginning at amino acid 126 of total of 635. This is expected to result in a premature truncation of the functional protein leading to loss of functional domains, which would lead to loss of function. It is interesting that our case documents the occurrence of a clinical picture consistent with ET in a patient with this mutation.

![Structure of MPL receptor and location of the 2 reported mutations. Both mutations are in the extracellular domain.](hr-11-1-7868-g001){#fig001}

###### 

Mutations reported in MPL gene.

  Mutation                           type                              Clinical effect                                                                                  Comments \[Ref.\]
  ---------------------------------- --------------------------------- ------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *K39N*                             Polymorphism                      Familial thombocytosis.                                                                          Approximately 7% of African Americans are heterozygous for this polymorphism \[[@ref11]\]
  *P106L*                            Germline                          Familial thrombocytosis                                                                          Prevalence was 3.3% in a cohort of unrelated individuals from Arabic descent \[[@ref12]\]
  *T119I*                            Somatic                           Gain-of-function when analyzed in functional assays                                              \[[@ref13]\]
  *F126fs\*5*                        Somatic                                                                                                                            Described in this report in a patient with clinical picture of ET
  *S204F*                            Somatic                           Gain-of-function when analyzed in functional assays                                              \[[@ref13]\]
  *S204P*                            Somatic                           Weak gain-of-function mutation                                                                   \[[@ref14]\]
  *E230G*                            Somatic                           Gain-of-function when analyzed in functional assays                                              \[[@ref13]\]
  *Y252H*                            Somatic                           Described in 2011 in a three year old African American female with a JAK2 mutation-negative ET   Described in an adult patient with ET in this report \[[@ref15]\]
  *V285E*                            Germline                          Felt to be associated with HT                                                                    Activating germline mutations in exon 6 identified in 2016 in a case initially diagnosed as primary myelofibrosis \[[@ref13]\]
  *R321W*                            Germline                          Felt to be associated with HT                                                                    Activating germline mutations in exon 6 identified in 2016 in a case initially diagnosed as ET \[[@ref13]\]
  *T487A*                            Somatic                           Acute megakaryoblastic leukaemia                                                                 Induces myeloproliferative disorder in mice \[[@ref16]\]
  *T496-A497 ALVI ins*               Somatic                           Reported in a patient with PMF                                                                   \[[@ref17]\]
  *V501L*                                                              Reported in a patient with JAK2 negative MPN                                                     Patient had also *S505N* mutation \[[@ref17]\]
  *S505N*                            In most cases germline mutation   Hereditary thrombocythemia                                                                       Inherited in an autosomal dominant pattern, but reported as a somatic mutation in sporadic cases as well \[[@ref9],[@ref10]\]
  *A506T*                            Somatic                           Not gain-of-function mutation based on *in vitro* studies                                        Both *A506T* and *A519T* mutations were found in a patient with PMF in association with *JAK2 V617F* \[[@ref8]\]
  *V507I*                                                              Reported in a patient with JAK2 negative MPN                                                     \[[@ref17]\]
  *L510P*                            Somatic                           Not gain-of-function mutation based on *in vitro* studies                                        \[[@ref8]\]
  *R514K*                                                              Reported in a patient with JAK2 negative MPN                                                     \[[@ref17]\]
  *W515L W515K*                      Somatic                           Essential thrombocythemia                                                                        Most common mutations in MPL
  W515A W515R                        Somatic                           Essential thrombocythemia                                                                        Given the extremely low mutation rate of W515A/R, the clinical significance is not confirmed but they are reported to function like W515K/L
  *W515S W515G*                      Somatic                           Detected in patient with JAK2 negative MPN                                                       \[[@ref17]\]
  *W515-P518* Somatic *del/ins KT*   MPN                               Patient had MPN not otherwise specified \[[@ref17]\]                                             
  *A519T*                            Somatic                           Not gain-of-function mutation based on *in vitr*o studies                                        Both *A506T* and *A519T* mutations were found in a patient with PMF in association with JAK2 V617F \[[@ref8]\]
  *A519V*                                                              Reported in a patient with JAK2 negative MPN                                                     \[[@ref17]\]
  *R525C fs\*14*                     Somatic                           Patient had confirmed chronic MPN not otherwise specified                                        Exon 11 mutation involving a deletion of 2 nucleotides (AG) and insertion of T with subsequent frameshift and a stop codon after 13 amino acids \[[@ref17]\]
  *D545G D545N*                      Somatic                           Reported in a patient with JAK2 negative MPN                                                     Exon 11 \[[@ref17]\]
  *Y591D*                            Somatic                           ET                                                                                               Found on exon 12 in a patient who was initially diagnosed with triple negative ET. This patient, however, developed *JAK2 V617F* mutation at 5.5 years follow-up \[[@ref13]\]
  *Y591N*                            Somatic                           Weak gain-of-function mutation                                                                   \[[@ref14]\]
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